Catalyst Biosciences Inc   (CBIO)
Other Ticker:  
Price: $0.5113 $-0.01 -2.647%
Day's High: $0.5796 Week Perf: 18.58 %
Day's Low: $ 0.48 30 Day Perf: 6.01 %
Volume (M): 484 52 Wk High: $ 0.74
Volume (M$): $ 247 52 Wk Avg: $0.34
Open: $0.57 52 Wk Low: $0.19

 Market Capitalization (Millions $) 19
 Shares Outstanding (Millions) 38
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 29
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 0

Catalyst Biosciences Inc
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company that focuses on developing novel medications for rare and debilitating diseases. The company utilizes its proprietary protease engineering platform to create therapeutics that target specific proteases in the body, regulating their activity to treat various disorders.

Catalyst Biosciences primarily focuses on developing therapies for diseases related to the complement and coagulation systems. These areas include rare bleeding disorders, hemophilia, and hereditary angioedema. The company's lead product candidate, marzeptacog alfa, is being developed as a subcutaneous therapy for individuals with hemophilia A or B with inhibitors.

Besides marzeptacog alfa, Catalyst Biosciences has a pipeline of additional drug candidates in various stages of development. The company aims to improve upon existing treatments or develop new therapies where there are currently unmet medical needs. Catalyst Biosciences collaborates with industry partners and academic institutions to drive research and development efforts.

The company's objective is to create novel treatments that have the potential to transform the lives of patients suffering from rare, serious, or chronic diseases. Through its innovative protease engineering technology and strategic partnerships, Catalyst Biosciences strives to bring new therapeutic options to patients and improve their quality of life.

   Company Address: 12770 High Bluff Drive San Diego 92130 CA
   Company Phone Number: 266-8674   Stock Exchange / Ticker: NASDAQ CBIO
   CBIO is expected to report next financial results on March 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Catalyst Biosciences Inc

Catalyst Biosciences Inc. Reports Dramatic 70% Improvement in Financial Performance in Third Quarter of 2023

As industry experts delve into the third quarter of 2023 financial results, all eyes are on Catalyst Biosciences Inc., a major player in the Pharmaceutical Preparations industry. With its operating shortfall of $-1.623 million and lack of specified revenue for the reporting period from July to September 30, 2023, analysts are keen to explore the company's progress and understand the context behind these figures.
A Comparative Analysis
Comparing the third quarter of 2023 with the same period the previous year, it becomes evident that Catalyst Biosciences Inc. has made substantial strides in the right direction. In Q3 2022, the company faced an operating shortfall of $-5.166 million. However, during the July to September 30, 2023 fiscal span, the company managed to operate more economically, slashing the losses to $-1.576 million. This indicates a significant improvement of approximately 70% in operating performance.

Catalyst Biosciences Inc

Catalyst Biosciences Inc Faces Steep Decline in Operating Conduct Throughout Second Quarter of 2023

The stock market is always abuzz with excitement as investors eagerly await the latest financial updates from various sectors. In particular, the Major Pharmaceutical Preparations sector has caught the attention of insiders as they closely analyze the second quarter of 2023 numbers. One company that has piqued their interest is Catalyst Biosciences Inc (CBIO), which reported an operating loss of $-2.543 million for the aforementioned quarter.
Although CBIO has not disclosed its top-line figures yet, insiders are making smart efforts to frame the company's performance in the context of the prevailing stage of the organization. It becomes imperative, then, to compare it with the operating income of the second quarter of 2022, which stood at an impressive $51.53 million. This stark difference raises certain concerns among investors as they ponder whether Catalyst Biosciences Inc has the necessary stamina to execute a potential business strategy successfully.

Catalyst Biosciences Inc

Lackluster Revenue at Catalyst Biosciences Inc in Q1 2023 Raises Concerns about Financial Performance

As a human observer in the stock market, it is essential to exercise caution in investing in any sector. When it comes to the healthcare sector, we must take a closer look at the individual companies and their financials before making any investment decisions.
In the case of Catalyst Biosciences Inc, their overall receivables turnover ratio remained the same as the previous period, ranking at a low of -1.31. Although the company showed an improvement in profitability in the first quarter of 2023, with positive earnings per share of $0.01 compared to a loss of $-0.65 the previous year, we must also take note of the -99.04% drop in EPS from the preceding financial reporting period.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com